Patología Intestinal S 25 Manej o de la de c oliti s u lcer osa grave en Chi le - C. Agüero L . et al. 19.- Kang Y, Moon H, Lee S, Lim Y, Kang H. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci 2015; 60: 951-6. 20.- Jahnsen J, Detlie T, Vatn S, Ricanek P. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study. Expert Rev Gastroenterol Hepatol 2015; 9: 45-52. 21.- Gecse K, Lovasz B, Farkas K, Banai J, Bene L, Gasztonyi B, et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohn’s Colitis 2015; 10: 133- 40. 22.- Farkas K, Rutka M, Balint A, Nagy F, Bor R, Milassin A, et al. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis-experiences from a single center. Expert Opin Biol Ther 2015; 15: 1257-62. Gastroenterol. latinoam 2016; Vol 27, S upl Nº 1: S 22-S 25
Gastro_3
To see the actual publication please follow the link above